Friday, December 9, 2016

AstraZeneca's immunotherapy enters U.S. approval process

FRANKFURT, Dec 9 (Reuters) - AstraZeneca's

immunotherapy drug durvalumab, the British drugmaker's most

important pipeline medicine, has been accepted for review by

U.S. regulators against bladder cancer, potentially its first

use.

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)